Neisseria (e.g., Neisseria Gonorrhoeae, Etc.) Patents (Class 424/249.1)
-
Patent number: 8128942Abstract: The present invention provides an immunogenic conjugate comprising biologically deacylated gram-negative bacterial moieties linked to D. discoideum proteinase 1, as well as novel subunits thereof, and methods of making and using the conjugates in vaccines to treat sepsis and other infectious complications.Type: GrantFiled: May 21, 2010Date of Patent: March 6, 2012Assignee: EndoBiologics, IncorporatedInventors: Gary L. Gustafson, Dan C. DeBorde
-
Publication number: 20120052092Abstract: The present invention relates to an immunogenic composition comprising at least one modified factor H binding protein, wherein the composition is capable of eliciting an immune response, when administered to a human or non-human animal; and associated compositions, uses and kits.Type: ApplicationFiled: October 26, 2009Publication date: March 1, 2012Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Rachel Exley, Christoph Tang, Susan M. Lea
-
Publication number: 20120039942Abstract: The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally down-regulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection.Type: ApplicationFiled: August 17, 2011Publication date: February 16, 2012Applicants: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Martine Petronella Bos, Jan Poolman, Boris Tefson, Johannes Petrus Maria Tommassen
-
Patent number: 8114960Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.Type: GrantFiled: June 28, 2010Date of Patent: February 14, 2012Assignee: Novartis AGInventors: Maria Beatrice Arico, Maurizio Comanducci, Cesira Galeotti, Vega Masignani, Marzia Monica Guiliani, Mariagrazia Pizza
-
Publication number: 20120034261Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: ApplicationFiled: March 20, 2009Publication date: February 9, 2012Applicant: Wyeth Holdings CorporationInventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
-
Publication number: 20120027800Abstract: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.Type: ApplicationFiled: September 29, 2011Publication date: February 2, 2012Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Francois-Xavier Jacques Berthet, Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Patent number: 8101194Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: GrantFiled: October 11, 2002Date of Patent: January 24, 2012Assignee: Wyeth LLCInventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
-
Publication number: 20120003277Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the invention find use in, among other things, clinical (e.g., therapeutic and preventative medicine (e.g., vaccination)) and research applications.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicants: NANOBIO CORPORATION, THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: James R. Baker, JR., Tarek Hamouda, Susan M. Ciotti
-
Publication number: 20110300179Abstract: The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid molecule encoding an antigenic component thereof, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. The invention further provides an adjuvant composition for use in a method of vaccination, the composition comprising or consisting of a population of T cells, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic.Type: ApplicationFiled: November 12, 2007Publication date: December 8, 2011Inventors: Anna-Lena Spetz-Holmgren, Ulrika Johansson, Jan Andersson, Lilian Walther-Jallow
-
Publication number: 20110300171Abstract: The invention relates to immunization against pathogenic bacterial strains which express or can express multiple factor H binding proteins. Certain aspects of the invention include vaccine compositions comprising at least two factor H binding proteins derived from a pathogenic bacterial strain which expresses multiple facto H binding proteins.Type: ApplicationFiled: September 14, 2009Publication date: December 8, 2011Applicants: HUMANITAS MIRASOLE S.P.A., NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.Inventors: Silvana Savino, John Donnelly, Rino Rappuoli, Mariagrazia Pizza, Barbara Bottazzi
-
Publication number: 20110293723Abstract: Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.Type: ApplicationFiled: May 26, 2011Publication date: December 1, 2011Applicant: Selecta Biosciences, Inc.Inventors: Robert L. Bratzler, Grayson B. Lipford, Lloyd Johnston, Charles Zepp
-
Patent number: 8048433Abstract: The current invention provides new Gram negative polypeptides exhibiting lipid A 3-O-deacylase activity and are capable of modifying and/or detoxifying gram negative LPS. The present invention also provides Gram negative bacteria, Gram negative bacterial lipopolysaccharides (LPS) and compositions comprising LPS, which are provided with or treated with a 3-O-deacylase activity according to the invention and which may be used for pharmaceutical and/or veterinary purposes, in particular for the preparation of whole cell or acellular vaccines against pathogenic Gram negatives such as Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica.Type: GrantFiled: December 16, 2005Date of Patent: November 1, 2011Assignee: NVI Nederlands VaccininstituutInventors: Johannes Petrus Maria Tommassen, Peter André Van Der Ley, Jeroen Johannes Gerardus Geurtsen
-
Publication number: 20110250223Abstract: Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH2-A-[-X-L-]n-B—COOH where X is an amino acid sequence, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than I. Proteins where each of the n —X— moieties shares sequence identity to each other —X— moiety, the protein is a ‘tandem protein’.Type: ApplicationFiled: June 13, 2011Publication date: October 13, 2011Applicant: NOVARTIS VACCINESS AND DIAGNOSTICSInventor: Mariagrazia PIZZA
-
Patent number: 8029807Abstract: The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally downregulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection.Type: GrantFiled: November 3, 2009Date of Patent: October 4, 2011Assignees: GlaxoSmithKline Biologicals S.A., University of UtrechtInventors: Martine Petronella Bos, Jan Poolman, Boris Tefson, Johannes Petrus Maria Tommassen
-
Publication number: 20110189215Abstract: The present invention relates to immunogenic compositions comprising neisserial blebs with upregulated levels of the NMB0964 antigens such that bacterial antibodies are generated against said antigen. Methods are also provided to upregulate expression through removal of the zinc repression mechanism of the cell or promoter or through removal of zinc from the culture medium.Type: ApplicationFiled: March 6, 2009Publication date: August 4, 2011Inventors: Martine Petronella Bos, Jan Poolman, Michiel Stork, Johannes Petrus Maria Tommassen, Vincent Weynants
-
Publication number: 20110189187Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: ApplicationFiled: December 21, 2007Publication date: August 4, 2011Applicant: WyethInventor: Gary Warren Zlotnick
-
Publication number: 20110182981Abstract: The present invention relates to immunogenic compositions comprising a recombinant Neisseria gonorrhoeae OpcA and methods of eliciting an immune response in a mammal by administering a formulation comprising N. gonorrhoeae OpcA or a portion or fragment of N. gonorrhoeae OpcA. The invention also provides for methods and kits for diagnosing N. gonorrhoeae infection using said recombinant N. gonorrhoeae OpcA.Type: ApplicationFiled: August 24, 2009Publication date: July 28, 2011Inventor: Peixuan Zhu
-
Publication number: 20110171259Abstract: The present invention is directed toward adjuvants that effect an innate and/or a specific immune response. The adjuvants contain at least one lipoprotein, such as Lip, Lip fragments or Lip variants, where the lipoprotein comprises at least one pentameric unit and at least one lipid moiety. Adjuvants wherein the lipoprotein make up at least 10% of the adjuvant by weight/volume are provided.Type: ApplicationFiled: September 4, 2009Publication date: July 14, 2011Inventors: Martin Gagne, Daniel Larocque, Martin Plante
-
Publication number: 20110171234Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising o more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and m preventing and treating Neisseria infections.Type: ApplicationFiled: February 14, 2011Publication date: July 14, 2011Applicant: Isis Innovation LimitedInventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Patent number: 7947291Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.Type: GrantFiled: January 25, 2001Date of Patent: May 24, 2011Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings
-
Publication number: 20110033500Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB? is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions.Type: ApplicationFiled: October 21, 2010Publication date: February 10, 2011Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Patent number: 7871628Abstract: The present invention relates to peptide mimics of a conserved gonococcal epitope of Neisseria gonorrhoeae, which epitope is not found on human blood group antigens. This invention also relates to methods and compositions using such peptide mimics for the prophylaxis of gonorrheal infections.Type: GrantFiled: February 26, 2007Date of Patent: January 18, 2011Assignee: University of MassachusettsInventors: Peter A. Rice, Jutamas Ngampasutadol, Sunita Gulati
-
Publication number: 20100316675Abstract: The present invention is directed to nucleic acids encoding glycosyltransferases, the proteins encoded thereby, and to methods for synthesizing oligosaccharides using the glycosyltransferases of the invention. In particular, the present application is directed to identification a glycosyltransferase locus of Neisseria gonorrhoeae containing five open reading frames for five different glycosyltransferases. The functionally active glycosyltransferases of the invention are characterized by catalyzing reactions such as adding Gal ?1?4 to GlcNAc or Glc; adding GalNAc or GlcNAc ?1?3 to Gal; and adding Gal ?l?4 to Gal. The glycosyltransferases of the invention are particularly suited to the synthesis of the oligosaccharides Gal?1?4GlcNAc?1?3Gal?1?4Glc (a mimic of lacto-N-neotetraose), GalNAc?1?3Gal?1?4GlcNAc?1?3Gal?1?4Glc?1?4 (a mimic ganglioside), and Gal?1?4Gal?1?4Glc?1?4Hep?R (a mimic of the saccharide portion of globo-glycolipids).Type: ApplicationFiled: June 14, 2010Publication date: December 16, 2010Applicant: The Rockefeller UniversityInventor: Emil C. GOTSCHLICH
-
Patent number: 7838014Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and Opc, and PorA and OpA and OpC. Alternatively, or in addition, lgtB? is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions.Type: GrantFiled: July 31, 2003Date of Patent: November 23, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Patent number: 7838015Abstract: A combination of CpG oligonucleotides and polymer microparticles is an extremely effective adjuvant for Neisserial antigens. The invention therefore provides a composition comprising: (a) a Neisserial antigen; (b) a CpG oligonucleotide; and (c) a biodegradable polymer microparticle.Type: GrantFiled: October 3, 2002Date of Patent: November 23, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Derek O'Hagan, Nicholas Valiante
-
Publication number: 20100291137Abstract: The present invention provides an isolated refolded NspA protein, and a method of preparing it.Type: ApplicationFiled: January 25, 2010Publication date: November 18, 2010Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Ralph Biemans, Martine Bos, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants, Johannes Petrus Maria Tommassen
-
Publication number: 20100285135Abstract: Disclosed herein are sterile-filtered lyophilized nanoparticle compositions which contain at least one biodegradable polymer, at least one surfactant, at least one cryoprotective agent and at least one antigen. Also disclosed are methods of making and using such compositions and kits supplying such compositions.Type: ApplicationFiled: December 1, 2006Publication date: November 11, 2010Applicant: NOVARTIS AGInventors: Janet R. Wendorf, Manmohan Singh, Derek T. O'Hagan
-
Publication number: 20100272758Abstract: The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., E. coli) substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The present invention further provides methods of generating viable non-toxic Gram-negative bacteria and uses thereof. The present invention also provides compositions and methods for inducing immune responses and for researching and developing therapeutic agents.Type: ApplicationFiled: January 19, 2007Publication date: October 28, 2010Applicant: Regents of the University of MichiganInventors: Ronald Wesley Woodard, Timothy Charles Meredith, Parag Aggarwal
-
Patent number: 7820185Abstract: An OMV preparation comprises OMVs having a sufficiently positive or negative surface charge to substantially prevent aggregation.Type: GrantFiled: July 18, 2005Date of Patent: October 26, 2010Assignee: Health Protection AgencyInventors: Andrew R. Gorringe, Phillip Vincent, Denise Halliwell, Karen M. Reddin
-
Patent number: 7807181Abstract: Provided herein are mutant strains of Neisseria meningitidis which produce Kdo-free lipid A as well as the Kdo-free lipid A molecules and immunogenic compositions containing such Kdo-free lipid A molecules from a Neisseria strain containing a genetically stable mutation which inactivates a gene selected from the group consisting of genes encoding arabinose-5-phosphate isomerase, CMP-Kdo synthetase and CMP-Kdo transferase. N. meningitidis NMB206 is a specifically exemplified strain which harbors a stable insertion mutation in the gene (kpsF) encoding A5P isomerase; strain NMB-249 is a specifically exemplified strain with a stable insertion mutation in the gene (kdtA) encoding CMP-Kdo synthetase, and strain NMB259 is specifically exemplified strain with a stable insertion mutation in the gene (kdsB) encoding CMP-Kdo transferase. Also provided by the present invention are methods for the production of Lipid A flee of 3-keto-3-deoxyoctanoic acid using these genetically stable N. meningitidis mutants.Type: GrantFiled: March 20, 2003Date of Patent: October 5, 2010Assignee: Emory UniversityInventors: David S. Stephens, Yih-Ling Tzeng, Susu Zughaier, Shanta Zimmer
-
Patent number: 7807183Abstract: The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP (SEQ ID NO: 25). The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particularly brain cancer.Type: GrantFiled: July 19, 2006Date of Patent: October 5, 2010Assignee: The Board of Trustees of the University of IllinoisInventors: Chang Soo Hong, Tohru Yamada, Arsenio M. Fialho, Tapas K. Das Gupta, Ananda M. Chakrabarty
-
Patent number: 7803387Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.Type: GrantFiled: February 28, 2001Date of Patent: September 28, 2010Assignee: Novartis Vaccines and Diagnostics SRLInventors: Maria Beatrice Arico, Maurizio Comanducci, Cesira Galeotti, Vega Masignani, Marizia Monica Guiliani, Mariagrazia Pizza
-
Patent number: 7794733Abstract: Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and diagnosis of non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic disease. Antibodies are developed to these proteins and also useful in the compositions and methods described herein.Type: GrantFiled: June 26, 2003Date of Patent: September 14, 2010Assignee: The University of MontanaInventors: Ralph C. Judd, D. Scott Manning
-
Patent number: 7785608Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: GrantFiled: September 2, 2003Date of Patent: August 31, 2010Assignee: Wyeth Holdings CorporationInventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
-
Patent number: 7776335Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: GrantFiled: October 30, 2007Date of Patent: August 17, 2010Assignee: ID Biomedical CorporationInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Patent number: 7776342Abstract: This invention discloses means for obtaining immunogenic peptides, polypeptides, proteins, and their corresponding nucleic acid sequences, target cells with vaccine interest, or lysates thereof, without making structural changes in said antigens, through their association with Very Small Size Proteoliposomes. The object of the invention is to provide immunogenic compositions containing peptides, polypeptides, proteins, their corresponding DNA sequences, cells or their lysates and Very Small Size Proteoliposomes (VSSP), which are formed by binding the Outer Membrane Protein Complex (OMPC) of Neisseria meningitidis with gangliosides, by means of hydrophobic links. Additionally, it is stated that these compositions can be formulated alone or in the form of emulsions with the Incomplete Freund's Adjuvant (IFA), and may also be lyophilized.Type: GrantFiled: December 6, 2001Date of Patent: August 17, 2010Assignee: Centro de Immunologia MolecularInventors: Luis Enrique Fernandez Molina, Belinda Sanchez Ramirez, Eduardo Raul Suarez Pestana, Anabel de la Barrera Aira, Circe Mesa Pardillo, Joel de Leon Delgado, Yildian Diaz Rodriguez, Rolando Perez Rodriguez
-
Publication number: 20100172931Abstract: The present invention is related to field of medicine, particularly to the development of pharmaceutical composition containing the NMB1796 protein. The composition described in this invention are able to confer protection against different diseases caused or not by pathogenic agents. The NMB1796 protein was identified as a Neisseria meningitidis outer membrane vesicle (OMV) component, and it was obtained through recombinant DNA technology being its immunogenicity and protective activity evaluated in animal models. Due to the high level of conservation that the NMB1796 coding gene has shown, pharmaceutical compositions containing this protein have a high value as inducers of a cross-reactive immune response. The composition presented in this invention is applicable to the field of human medicine.Type: ApplicationFiled: June 16, 2008Publication date: July 8, 2010Inventors: Rolando Pajon Feyt, Olivia Niebla Perez, Gretel Sardinas Garcia, Sonia Gonzalez Blanco, Darien Garcia Diaz, Evelin Caballero Menendez, Karem Cobas Acosta
-
Publication number: 20100112078Abstract: The present invention provides a vaccine composition comprising an effective amount of antigen or a nucleic acid encoding antigen, encapsulated in polymeric particles, wherein said polymeric particles comprises nanoparticles, microparticles or combinations thereof, wherein surprisingly the nanoparticle induces cellular response and the microparticle induces humoral response. The invention further provides a method of inducing cellular and/or humoral immune response.Type: ApplicationFiled: September 25, 2009Publication date: May 6, 2010Applicant: NATIONAL INSTITUTE OF IMMUNOLOGYInventors: Amulya K. Panda, Kanchan Vibhu
-
Publication number: 20100047287Abstract: The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally down-regulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection.Type: ApplicationFiled: November 3, 2009Publication date: February 25, 2010Applicants: GLAXOSMITHKLINE S.A., UTRECHT UNIVERSITYInventors: Martine Petronella Bos, Jan Poolman, Boris Tefsen, Johannes Petrus Maria Tommassen
-
Patent number: 7666988Abstract: The invention provides BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and polynucleotides encoding BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: March 7, 2000Date of Patent: February 23, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Catherine Defrenne, Christine Delmelle, Jean-Louis Ruelle
-
Patent number: 7662399Abstract: The invention provides BASB047, BASB054, BASB068 and BASB069 polypeptides, and polynucleotides encoding BASB047, BASB054, BASB068 and BASB069 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: July 12, 2004Date of Patent: February 16, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventor: Jean-Louis Ruelle
-
Patent number: 7655245Abstract: The invention provides proteins from Neisseria meningitidis (strains A & B) and from Neisseria gonorrhoeae, including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.Type: GrantFiled: June 8, 2004Date of Patent: February 2, 2010Assignee: Novartis AGInventors: Vincenzo Scarlato, Vega Masignani, Rino Rappuoli, Mariagrazia Pizza, Guido Grandi
-
Patent number: 7648709Abstract: The present invention relates to the field of Immunology, specifically with the branch of Immuno-Allergy and in particular with the use of adjuvant or carrier compounds, capable of modulating the immune response to allergens. The technical objective that is pursued is to obtain a pharmaceutical preparation of therapeutic or prophylactic use using bacterial proteoliposomes, which transform the allergic response Th2 and IgE when being applied in allergic individuals, toward a protector response Th1; as well as it is able to prevent the appearance and the development of allergies in individuals non-allergic yet. The vaccine composition consists of proteoliposomes derived from Gram-negative bacteria coupled to allergens and optionally contains other adjuvants or antigens. The method for its preparation and an immunization scheme of two doses are provided.Type: GrantFiled: May 8, 2003Date of Patent: January 19, 2010Inventors: Miriam de San Juan Bosco Lastre González, Oliver Germán Pérez Martín, Alexis Labrada Rosado, Igor Bidot Martínez, Gustavo Rafael Bracho Granado, Judith Mónica Del Campo Alonso, Dainerys Aleida Pérez Lastre, Elisa Facenda Ramos, Caridad Zayas Vignier, Claudio Rodríguez Martínez, Victoriano Gustavo Sierra González, Jorge Ernesto Pérez Lastre
-
Patent number: 7628995Abstract: The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally downregulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection.Type: GrantFiled: December 21, 2004Date of Patent: December 8, 2009Assignees: GlaxoSmithKline Biologicals S.A., University of UtrechtInventors: Martine Petronella Bos, Jan Poolman, Boris Tefsen, Johannes Petrus Maria Tommassen
-
Publication number: 20090297551Abstract: This invention relates to a novel adjuvant comprising a transfection reagent, and to uses of this adjuvant. In particular, the adjuvant may be used in compositions for eliciting an immune response and in vaccines.Type: ApplicationFiled: March 19, 2007Publication date: December 3, 2009Applicant: ISIS INNOVATION LIMITEDInventors: Quentin Sattentau, Neil Sheppard
-
Patent number: 7618636Abstract: WO99/36544 discloses a large number of proteins from Neisseria Meningitidis. The present invention relates to fragments of those proteins which comprise at least one antigenic determinant. Homologous sequences and proteins comprising these fragments are also disclosed.Type: GrantFiled: July 13, 2000Date of Patent: November 17, 2009Assignee: Novartis Vaccines And Diagnostics SRLInventors: Vega Masignani, Vincenzo Scarlato, Maria Scarselli, Cesira L. Galeotti, Marirosa Mora
-
Publication number: 20090263421Abstract: The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid molecule encoding an antigenic component thereof, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. The invention further provides an adjuvant composition for use in a method of vaccination, the composition comprising or consisting of a population of T cells, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic.Type: ApplicationFiled: May 10, 2006Publication date: October 22, 2009Inventors: Anna-Lena Spetz-Holmgren, Ulrika Johansson, Jan Anderson, Lilian Walther-jallow
-
Patent number: 7604810Abstract: To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention provides proteins which comprise stretches of amino acid sequence that are shared across the majority of Neisseria, particularly N. meningitidis and N. gonorrhoeae.Type: GrantFiled: May 2, 2007Date of Patent: October 20, 2009Assignee: Novartis Vaccines and Diagnostics SRLInventor: Rino Rappuoli
-
Patent number: 7585510Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: October 2, 2000Date of Patent: September 8, 2009Assignee: ISIS Innovation LimitedInventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Richard Edward Moxon
-
Publication number: 20090123499Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and more effective for use in human subjects.Type: ApplicationFiled: June 8, 2007Publication date: May 14, 2009Inventors: Nathalie Devos, Christiane Feron, Jan Poolman, Vincent Weynants